IL1B and neoplasm: Inhibition of several tumor immunosuppressive cytokines blocking the inflammasome pathway are also in the clinic or under development, such as anti-IL-1bR, anti-IL-1, IRAK4 (130, 131) and IL-6 inhibitors (132).